Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03939689
Title Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Progenics Pharmaceuticals, Inc.
Indications

prostate adenocarcinoma

Therapies

Enzalutamide

131I-MIP-1095 + Enzalutamide

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.